- €2.57m
- €19.17m
- €33.25m
Brief: Paion Q1 Net Loss At EUR 1.7 Mln
Brief: Paion Closes Enrollment In EU Phase III Trial With Remimazolam In General Anesthesia
Brief: Paion FY Revenues At EUR 8.0 Mln
Brief: Paion: Mundipharma Gets Market Approval For Anerem In General Anesthesia In Japan
Brief: Paion Grants Remimazolam License For Southeast Asia To Hana Pharm
Brief: PAION To Submit New Drug Application For Remimazolam In South Korea
Brief: Paion Submits Marketing Authorization Application For Remimazolam
Brief: Paion End-Sept Cash And Cash Equivalents At EUR 22.8 Million
Brief: Paion And Yorkville Sign Agreement On Issue Of Convertible Notes
Brief: Paion Appoints James Phillips As CEO
Brief: Paion H1 Net Result Turns To Profit Of EUR 0.6 Million
Brief: Paion And European Investment Bank Sign Financing Agreement For EUR 20 Million
Brief: Paion Says FDA Accepted New Drug Application For Remimazolam In The U.S.
Brief: Paion Q1 Net Loss At EUR 3.2 Mln
Brief: Paion - Submission Of New Drug Application In U.S
Brief: Paion Sees Net Loss Of About EUR 7 Mln - EUR 10 Mln In 2019
Brief: Paion Announces Submission Of New Drug Application For Remimazolam In Japan
Brief: Paion Announces That NMPA Accepts Submission Of New Drug Application For Remimazolam By Chinese Licensee Yichang Humanwell
Brief: Paion 9-Mth Net Loss At EUR 8.8 Mln